Literature DB >> 7247383

Single-dose pharmacokinetics of acyclovir.

S A Spector, J D Connor, M Hintz, R P Quinn, M R Blum, R E Keeney.   

Abstract

The pharmacokinetics of intravenously administered acyclovir were studied in 10 patients with advanced malignancies. After doses of 0.5 and 1.0 mg/kg, the slow disposition half-life values (t1/2beta) ranged from 2.2 to 3.1 h for the 1-h infusions and from 1.8 to 3.7 h for the 6-h infusions. Plasma levels, measured by radioimmunoassay, reached a maximum at the end of the 1-h infusions and approached steady state at 3 to 4 h into the 6-h infusions. Mean peak plasma concentrations obtained at 0.5 and 1.0 mg/kg administered over 1 h were 3.03 and 5.99 microM, respectively. Mean peak levels for the 6-h infusions were 1.07 microM at 0.5 mg/kg and 2.58 microM at 1.0 mg/kg. The mean urinary elimination of acyclovir was 44.7% of the administered doses. No clinical or laboratory abnormalities were noted in the 10 patients studied.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7247383      PMCID: PMC181487          DOI: 10.1128/AAC.19.4.608

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

3.  Effect of 9-(2-hydroxyethoxymethyl)guanine on herpesvirus-induced keratitis and iritis in rabbits.

Authors:  H E Kaufman; E D Varnell; Y M Centifanto; S D Rheinstrom
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

Review 4.  Drug therapy: antiviral agents (second of two parts).

Authors:  M S Hirsch; M N Swartz
Journal:  N Engl J Med       Date:  1980-04-24       Impact factor: 91.245

Review 5.  Drug therapy: antiviral agents (first of two parts).

Authors:  M S Hirsch; M N Swartz
Journal:  N Engl J Med       Date:  1980-04-17       Impact factor: 91.245

6.  Growth inhibition by acycloguanosine of herpesviruses isolated from human infections.

Authors:  C S Crumpacker; L E Schnipper; J A Zaia; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

7.  Acyclovir kinetics after intravenous infusion.

Authors:  P de Miranda; R J Whitley; M R Blum; R E Keeney; N Barton; D M Cocchetto; S Good; G P Hemstreet; L E Kirk; D A Page; G B Elion
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

8.  A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine].

Authors:  R P Quinn; P de Miranda; L Gerald; S S Good
Journal:  Anal Biochem       Date:  1979-10-01       Impact factor: 3.365

9.  Therapy of experimental herpes simplex encephalitis with aciclovir in mice.

Authors:  N H Park; D Pavan-Langston; S L McLean; D M Albert
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

10.  Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice.

Authors:  H J Field; S E Bell; G B Elion; A A Nash; P Wildy
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

View more
  10 in total

1.  Pediatrics-epitomes of progress: treatment of disseminated herpes infections in newborns and infants.

Authors:  S A Spector
Journal:  West J Med       Date:  1982-04

Review 2.  Clinical pharmacokinetics of acyclovir.

Authors:  O L Laskin
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

3.  Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection.

Authors:  T A Tartaglione; A C Collier; K Opheim; F G Gianola; J Benedetti; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans.

Authors:  O L Laskin; J A Longstreth; R Saral; P de Miranda; R Keeney; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

5.  Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans.

Authors:  O L Laskin; P de Miranda; D H King; D A Page; J A Longstreth; L Rocco; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

Review 6.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 7.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

8.  Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients.

Authors:  R Brigg Turner; Aaron Cumpston; Michael Sweet; Frank Briggs; Douglas Slain; Sijin Wen; Michael Craig; Mehdi Hamadani; William Petros
Journal:  Antimicrob Agents Chemother       Date:  2016-01-11       Impact factor: 5.191

Review 9.  Is Antimicrobial Treatment Effective During Therapeutic Plasma Exchange? Investigating the Role of Possible Interactions.

Authors:  Łukasz J Krzych; Marcelina Czok; Zbigniew Putowski
Journal:  Pharmaceutics       Date:  2020-04-25       Impact factor: 6.321

10.  Pharmacokinetics and analytical determination of acyclovir in Asian elephant calves (Elephas maximus).

Authors:  Siripat Khammesri; Chadarat Ampasavate; Darunee Hongwiset; Raktham Mektrirat; Siriluk Sangsrijan; Janine L Brown; Chatchote Thitaram
Journal:  Vet Anim Sci       Date:  2021-12-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.